Development and Characterization of Controlled Release Tablets of Candesartan Cilexetil/Β-Cyclodextrin Inclusion Complex

Abstract

Objective: Matrix tablet approach is one of the delivery systems intended for poorly water-soluble drugs like candesartan cilexetil. Candesartan cilexetil is a class II drug used for the treatment of hypertension.
 Methods: Matrix tablets from (F1x to F18z) were prepared in the presence of β-cyclodextrin. Matrix tablet formulation ensures control release of the drug and higher dissolution by β-cyclodextrin. Fourier transform infrared spectroscopy and differential scanning calorimetry were used to study compatibility.
 Results:The angle of repose determination showed good flow for most of the formulas besides having good compressibility. Weight variation test for all formulas showed accepted value. Drug content measurement showed accepted values. Friability and hardness of tablets were within the allowed values. Higher tablet swelling was obtained for the formulas containing hydroxy propyl methyl cellulose (HPMC) K100M (F3x and F15z) in which the ratio of the polymer was (1:1) and (1:3) respectively. In vitro release showed that F1x to F13z were studied depends on the type and amount of polymer i.e. (1:1), (1:2) and (1:3) respectively. F1x release after 8h was 95% which contain (1:1) polymer ratio in compare to F3x, which showed 85% after 8h, Which include 1:3 (drug: HPMC K100). Kinetic studies showed a zero-order model.
 Conclusion: The use of β-cyclodextrin modify the release profile of the drug, and control the sustained release formulas. The lower the time of the release but in a range that a sustained release of the drug was observed in compare with the formulas prepared without β-cyclodextrin.